Regeneron Pharmaceuticals Inc
$ 784.97
0.16%
26 Dec - close price
- Market Cap 83,196,961,000 USD
- Current Price $ 784.97
- High / Low $ 788.01 / 778.04
- Stock P/E 18.83
- Book Value 301.15
- EPS 41.68
- Next Earning Report 2026-02-03
- Dividend Per Share $2.64
- Dividend Yield 0.34 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.15 %
- 52 Week High 792.77
- 52 Week Low 475.17
About
Regeneron Pharmaceuticals, Inc. is a prominent American biotechnology firm headquartered in Westchester County, New York, renowned for its pioneering work in monoclonal antibodies and therapeutic proteins. The company excels in various therapeutic areas, notably oncology, ophthalmology, and immunology, with leading products like Eylea and Dupixent contributing significantly to its growth. With a robust pipeline of innovative therapies in development, Regeneron is committed to advancing scientific research and addressing critical unmet medical needs, solidifying its influential position within the biopharmaceutical sector.
Analyst Target Price
$795.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-01 | 2025-04-29 | 2025-02-04 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-02 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-03 |
| Reported EPS | 11.83 | 12.89 | 8.22 | 12.07 | 12.46 | 11.56 | 9.55 | 11.86 | 11.59 | 10.24 | 10.09 | 12.56 |
| Estimated EPS | 9.67 | 8.44 | 8.48 | 11.19 | 11.7 | 10.61 | 10.09 | 10.73 | 10.72 | 9.84 | 9.56 | 10.03 |
| Surprise | 2.16 | 4.45 | -0.26 | 0.88 | 0.76 | 0.95 | -0.54 | 1.13 | 0.87 | 0.4 | 0.53 | 2.53 |
| Surprise Percentage | 22.3371% | 52.7251% | -3.066% | 7.8642% | 6.4957% | 8.9538% | -5.3518% | 10.5312% | 8.1157% | 4.065% | 5.5439% | 25.2243% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 8.06 |
| Currency | USD |
Previous Dividend Records
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | |
|---|---|---|---|---|
| Payment Date | 2025-12-05 | 2025-09-03 | 2025-06-06 | 2025-03-20 |
| Amount | $0.88 | $0.88 | $0.88 | $0.88 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: REGN
2025-12-28 11:48:50
TB Alternative Assets Ltd. significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 174.0% in Q3, now holding 8,652 shares valued at $4.865 million. This makes Regeneron its 27th-largest position. The company also reported strong quarterly earnings, topping analyst estimates, and announced a quarterly dividend.
2025-12-28 08:08:41
Bellecapital International Ltd. increased its holdings in Regeneron Pharmaceuticals (NASDAQ:REGN) by 8.9%, purchasing 2,276 shares to own a total of 27,779 shares valued at $15.62 million. This move makes Regeneron its 16th largest holding, comprising about 2.5% of its portfolio. Other institutions like Dodge & Cox and Norges Bank also significantly increased their stakes, bringing institutional ownership to approximately 83.3%.
2025-12-27 16:55:37
This article provides a comprehensive weekend update on Merck (MRK) stock, covering its recent performance, key headlines including market positioning and short interest data, and ongoing policy and pipeline developments. It outlines Wall Street's forecasts, analyst targets, and upcoming earnings dates, offering investors key considerations before markets reopen on Monday.
2025-12-27 09:17:26
Cwm LLC recently increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 50.4%, bringing its total holding to 53,406 shares valued at approximately $30.03 million. Other institutional investors also adjusted their positions in the biopharmaceutical company, which recorded strong Q3 earnings, surpassing analyst expectations for both EPS and revenue. Regeneron also announced a quarterly dividend and currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $779.45.
2025-12-27 08:08:40
Beacon Investment Advisory Services Inc. significantly reduced its stake in Regeneron Pharmaceuticals by 51% in the third quarter of 2025. Despite this sale, Regeneron reported strong Q3 earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating among analysts with an average price target of $779.45. The biopharmaceutical company also recently declared a quarterly dividend of $0.88 per share.
2025-12-27 04:08:11
Morgan Stanley analyst Terence Flynn raised the price target for Regeneron Pharmaceuticals (REGN) to $768, maintaining an Equal Weight rating, believing policy concerns that impacted biopharma will lessen in 2026. The company also recently received marketing and manufacturing authorization in Japan for Dupixent (dupilumab) to treat bronchial asthma in children, expanding its earlier approval. Regeneron and Sanofi continue to explore dupilumab's potential in various other conditions with ongoing Phase 3 trials.
